Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for asparaginase

  1. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA408

  2. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  3. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

    Technology appraisal guidance
    Discontinued